{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Treatment will be permanently discontinued if any of the following occurs:', 'If the LSR(s) do(es) not resolve with the interruption of therapy for 2 weeks, or', 'If the LSR(s) recur(s) during bid dosing, or', 'If a third drug interruption is needed.', '7.5', 'Subject Discontinuation/Withdrawal from the Study', 'Subjects may be discontinued/withdrawn from the study for reasons that include, but are not', 'limited to, the following:', 'A subject may withdraw from the study at any time at his/her own request, or he/she may', 'be withdrawn at any time at the discretion of the Investigator for safety, behavioral,', 'compliance, or administrative reasons.', 'If the subject withdraws consent for disclosure of future information, the Sponsor may', 'retain and continue to use any data collected before such a withdrawal of consent.', 'If a subject withdraws from the study, he/she may request destruction of any samples taken', 'and not tested, and the Investigator must document this in the study center study records.', 'See Section 1.2 for the data to be collected at the time of study discontinuation and', 'follow-up and for any further evaluations that need to be completed.', 'The discontinuation of specific study centers or of the study are handled as part of Appendix 2.', '7.6', 'Lost to Follow-Up', 'A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled', 'visits and the study center is unable to contact him/her as described below.', 'The following actions must be taken if a subject fails to return to the clinic for a required study', 'visit:', 'The study center must attempt to contact the subject and reschedule the missed visit as soon', 'as possible and counsel the subject on the importance of maintaining the assigned visit', 'schedule and ascertain whether the subject wishes to and/or should continue in the study.', 'Before a subject is deemed lost to follow-up, the Investigator or designee must make every', 'effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary,', \"a certified letter to the subject's last known mailing address or local equivalent methods).\", \"These contact attempts should be documented in the subject's medical record.\", 'If the subject continues to be unreachable, he/she will be considered to have withdrawn', 'from the study and lost to follow-up.', '33']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '8.0 STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the Schedule of Activities (Section 1.2).', 'Adherence to the study design requirements, including those specified in the Schedule of Activities,', \"is essential and required for study conduct. Procedures conducted as part of the subject's routine\", 'clinical management (eg, blood count) and obtained before signing the informed consent form', '(ICF) may be utilized for Screening or Baseline purposes provided the procedures met the', 'protocol-specified criteria and were performed within the time frame defined in the Schedule of', 'Activities.', 'All Screening evaluations must be completed and reviewed to confirm that potential subjects meet', 'all eligibility criteria. The Investigator will maintain a screening log to record the details of all', 'subjects screened and to confirm eligibility or record reasons for screening failure, as applicable.', \"Protocol waivers or exemptions may be permitted at the Sponsor's discretion, especially when\", 'mitigating factors associated with a global pandemic and other situations that arise that are outside', 'the control of the Sponsor and/or Investigator. Immediate safety concerns should be discussed with', 'the Sponsor immediately upon occurrence or awareness to determine if the subject should continue', 'or discontinue study treatment.', '8.1', 'Study Visits', 'This study will consist of 6 visits as described in the Schedule of Activities (Section 1.2). The', 'maximum amount of blood collected from each subject over the duration of the study will be', 'approximately 20 mL. Repeat or unscheduled samples may be taken for safety reasons or for', 'technical issues with the samples.', '8.1.1', 'Visit 1 (Screening)', 'Screening will occur at Visit 1 (Day -90 to Day -7). Subjects can be screened for the study up to', 'approximately 90 days before Baseline. During Screening, the study requirements and procedures', 'will be reviewed and written informed consent/assent will be obtained prior to the initiation of any', 'study-related procedures. Following informed consent, a review of inclusion exclusion will be', 'conducted so that the Investigator can assess if the subject is likely to be eligible for enrollment.', 'Once this is confirmed, the availability of genetic testing confirming the diagnosis of CI and', 'specific subtype will be addressed. Subjects who already have had genetic test documenting', 'ARCI-LI or RXLI types of CI will not be required to provide samples for genetic testing. However,', 'the subject must provide the Investigator with a copy of the genetic report for the source', 'documentation file. Subjects requiring genetic testing, will have a buccal specimen obtained and', 'sent for analysis. Following confirmation of the appropriate genetic subtype, the following', 'procedures will be completed in the Screening period; Demographics, medical history,', 'concomitant medications, physical exam, vital signs, clinical evaluation of extent and location of', 'CI, percent BSA with CI in the Treatment Area, as well as in the VIIS Assessment Area, and', '34']\n\n###\n\n", "completion": "END"}